AI Engines For more Details: Perplexity Kagi Labs You
Improvement in Cognitive Function: Galanthamine hydrobromide has been shown to improve cognitive function, including memory, attention, and executive function, in patients with Alzheimer's disease and other forms of dementia. By inhibiting the breakdown of acetylcholine, it enhances cholinergic neurotransmission, which is impaired in Alzheimer's disease.
Slowing of Disease Progression: While galanthamine hydrobromide does not cure Alzheimer's disease, it may help slow the progression of symptoms in some patients. By preserving acetylcholine levels and enhancing cholinergic neurotransmission, it may help maintain cognitive function and delay cognitive decline over time.
Enhancement of Daily Functioning: Treatment with galanthamine hydrobromide may improve patients' ability to perform activities of daily living, such as dressing, grooming, and meal preparation, by helping to preserve cognitive function and independence.
Reduction in Behavioral Symptoms: Galanthamine hydrobromide may also reduce behavioral and psychological symptoms associated with dementia, such as agitation, aggression, and hallucinations. By improving cognitive function and enhancing neurotransmission, it may help stabilize mood and behavior.
Side Effects: Common side effects of galanthamine hydrobromide include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. These side effects are usually mild to moderate in severity and often improve with continued use or dose adjustment.
Cholinergic Side Effects: Due to its mechanism of action, galanthamine hydrobromide can cause cholinergic side effects, such as bradycardia, syncope, urinary incontinence, and exacerbation of asthma or obstructive pulmonary disease. Patients with underlying cardiovascular or respiratory conditions may be at higher risk for these side effects.
Dosage and Titration: Galanthamine hydrobromide is typically initiated at a low dose and gradually titrated upward to minimize side effects and maximize therapeutic benefit. Close monitoring is required during dose titration to assess tolerability and response.
Interactions: Galanthamine hydrobromide may interact with other medications, particularly those with anticholinergic properties, such as certain antidepressants, antipsychotics, and antihistamines. Concurrent use of these medications may increase the risk of cholinergic side effects.
Contraindications: Galanthamine hydrobromide is contraindicated in patients with a history of hypersensitivity to the drug or its components, as well as in patients with severe liver or kidney impairment. It should be used with caution in patients with gastrointestinal disorders or urinary obstruction.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.2 | -0.2 | |
ADHD | 1.9 | 0.3 | 5.33 |
Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
Allergic Rhinitis (Hay Fever) | 0.7 | 1 | -0.43 |
Allergies | 3.4 | 1 | 2.4 |
Allergy to milk products | 0.9 | 0.4 | 1.25 |
Alopecia (Hair Loss) | 0.8 | 0.8 | |
Alzheimer's disease | 1.2 | 2.3 | -0.92 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.6 | 0.67 |
Ankylosing spondylitis | 2 | 0.3 | 5.67 |
Anorexia Nervosa | 1.3 | -1.3 | |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 1 | 0.6 | 0.67 |
Atherosclerosis | 0.5 | 1 | -1 |
Atrial fibrillation | 1.4 | 0.6 | 1.33 |
Autism | 4.2 | 3.3 | 0.27 |
Barrett esophagus cancer | 0.2 | 0.1 | 1 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.4 | 0.9 | -1.25 |
Brain Trauma | 0.5 | 0.4 | 0.25 |
Carcinoma | 1.9 | 1.4 | 0.36 |
Celiac Disease | 1 | 1.8 | -0.8 |
Cerebral Palsy | 0.9 | 0.9 | 0 |
Chronic Fatigue Syndrome | 2.3 | 2.4 | -0.04 |
Chronic Kidney Disease | 0.6 | 0.6 | 0 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.4 | 0.75 |
Chronic Urticaria (Hives) | 1.2 | 0.1 | 11 |
Coagulation / Micro clot triggering bacteria | 0.7 | 0.9 | -0.29 |
Colorectal Cancer | 1.7 | 0.5 | 2.4 |
Constipation | 0.4 | 0.7 | -0.75 |
Coronary artery disease | 0.3 | 0.7 | -1.33 |
COVID-19 | 6 | 5.3 | 0.13 |
Crohn's Disease | 3.2 | 2 | 0.6 |
cystic fibrosis | 0.6 | 0.6 | 0 |
deep vein thrombosis | 0.6 | 0.4 | 0.5 |
Depression | 4.3 | 3.3 | 0.3 |
Dermatomyositis | 0.1 | 0.2 | -1 |
Eczema | 0.5 | 0.8 | -0.6 |
Endometriosis | 1.7 | 0.5 | 2.4 |
Eosinophilic Esophagitis | 0.2 | -0.2 | |
Epilepsy | 1.4 | 0.9 | 0.56 |
Fibromyalgia | 1.3 | 0.7 | 0.86 |
Functional constipation / chronic idiopathic constipation | 2.1 | 1.3 | 0.62 |
gallstone disease (gsd) | 1.4 | 0.5 | 1.8 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.9 | -3.5 |
Generalized anxiety disorder | 1 | 1 | 0 |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0 | 0 | |
Graves' disease | 0.6 | 1.1 | -0.83 |
Halitosis | 0.4 | 0.1 | 3 |
Hashimoto's thyroiditis | 1.3 | 0.3 | 3.33 |
Hidradenitis Suppurativa | 0.1 | 0.2 | -1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.7 | 0.4 | 3.25 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
hyperglycemia | 0.2 | 0.9 | -3.5 |
Hyperlipidemia (High Blood Fats) | 0.5 | 0.3 | 0.67 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1 | 2.5 | -1.5 |
Hypothyroidism | 0.9 | -0.9 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 1.1 | -1.1 | |
Inflammatory Bowel Disease | 1.9 | 2.6 | -0.37 |
Insomnia | 0.7 | 0.5 | 0.4 |
Intelligence | 0.3 | 0.3 | |
Intracranial aneurysms | 0.6 | 0.3 | 1 |
Irritable Bowel Syndrome | 2.3 | 1.4 | 0.64 |
Liver Cirrhosis | 2.4 | 1.6 | 0.5 |
Long COVID | 2.7 | 4.3 | -0.59 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 0.5 | 0.7 | -0.4 |
ME/CFS with IBS | 0.4 | 1.6 | -3 |
ME/CFS without IBS | 1.3 | 0.8 | 0.63 |
Menopause | 1.2 | 1.2 | |
Metabolic Syndrome | 3.9 | 3.5 | 0.11 |
Mood Disorders | 5.8 | 3.5 | 0.66 |
multiple chemical sensitivity [MCS] | 0.6 | 0.4 | 0.5 |
Multiple Sclerosis | 2.5 | 1.6 | 0.56 |
Multiple system atrophy (MSA) | 0.8 | 0.7 | 0.14 |
Neuropathy (all types) | 0.6 | 0.2 | 2 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 2.8 | -1 |
NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
Obesity | 4.3 | 1.8 | 1.39 |
obsessive-compulsive disorder | 3.3 | 1.2 | 1.75 |
Osteoarthritis | 0.9 | 0.1 | 8 |
Osteoporosis | 1.2 | 0.7 | 0.71 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 1.4 | 1.4 | 0 |
Polycystic ovary syndrome | 1.1 | 1.1 | 0 |
Postural orthostatic tachycardia syndrome | 0.3 | 0.2 | 0.5 |
Premenstrual dysphoric disorder | 0.9 | 0.9 | |
primary biliary cholangitis | 0.2 | 0.3 | -0.5 |
Psoriasis | 2.6 | 0.6 | 3.33 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1.8 | 0.56 |
Rosacea | 0.3 | 0.6 | -1 |
Schizophrenia | 3.5 | 1.3 | 1.69 |
scoliosis | 0 | 0.2 | 0 |
Sjögren syndrome | 1.6 | 1.4 | 0.14 |
Sleep Apnea | 0.7 | 1.1 | -0.57 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.3 | 0.67 |
Stress / posttraumatic stress disorder | 1.6 | 1.5 | 0.07 |
Systemic Lupus Erythematosus | 1.6 | 1.2 | 0.33 |
Tic Disorder | 0.2 | 0.6 | -2 |
Tourette syndrome | 0 | 0.2 | 0 |
Type 1 Diabetes | 1.5 | 1.2 | 0.25 |
Type 2 Diabetes | 3.6 | 2.4 | 0.5 |
Ulcerative colitis | 1.9 | 1.6 | 0.19 |
Unhealthy Ageing | 1.6 | 0.7 | 1.29 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.